0001104659-19-005522.txt : 20190204
0001104659-19-005522.hdr.sgml : 20190204
20190204160729
ACCESSION NUMBER: 0001104659-19-005522
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190131
FILED AS OF DATE: 20190204
DATE AS OF CHANGE: 20190204
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Sender Gary
CENTRAL INDEX KEY: 0001659085
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37558
FILM NUMBER: 19563746
MAIL ADDRESS:
STREET 1: C/O SYNERGY PHARMACEUTICALS INC.
STREET 2: 420 LEXINGTON AVE
CITY: NEW YORK
STATE: NY
ZIP: 10020
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Nabriva Therapeutics plc
CENTRAL INDEX KEY: 0001641640
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: L2
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 56 FITZWILLIAM SQUARE
CITY: DUBLIN
STATE: L2
ZIP: 2
BUSINESS PHONE: (610) 816-6640
MAIL ADDRESS:
STREET 1: 1000 CONTINENTAL DRIVE
STREET 2: SUITE 600
CITY: KING OF PRUSSIA
STATE: PA
ZIP: 19406
FORMER COMPANY:
FORMER CONFORMED NAME: Nabriva Therapeutics AG
DATE OF NAME CHANGE: 20150507
4
1
a4.xml
4
X0306
4
2019-01-31
0
0001641640
Nabriva Therapeutics plc
NBRV
0001659085
Sender Gary
1000 CONTINENTAL DRIVE
SUITE 600
KING OF PRUSSIA
PA
19406
0
1
0
0
Chief Financial Officer
Stock Options
2019-01-31
4
A
0
138200
0.00
A
2029-01-31
Ordinary Shares
138200
138200
D
Restricted Stock Units
2019-01-31
4
A
0
52500
0.00
A
2023-01-31
Ordinary Shares
52500
52500
D
The exercise price is $1.90 per share.
This option was granted on January 31, 2019. Vesting began on January 31, 2019 and ends on January 31, 2023. Twenty-five percent (25%) of the option award will vest on the one (1) year anniversary of the date of grant, and the remaining seventy-five percent (75%) of the option award will vest on a monthly pro-rata basis over the remaining vesting period.
The restricted stock unit shall convert into ordinary shares on a one-for-one basis upom vesting of the units.
The restricted stock unit award was granted on January 31, 2019. Vesting began on January 31, 2019 and ends on January 31, 2023. Twenty-five percent (25%) of the restricted stock unit award will vest on the one (1) year anniversary of the date of grant, and the remaining seventy-five percent (75%) of the restricted stock unit award will vest on a monthly pro-rata basis over the remaining vesting period.
/s/ Robert Crotty, by power of attorney
2019-02-04